RxDoctor Payments Data

Amanda Thomas, DO

Family Medicine · Grand Blanc, MINPI 1457975831

Payments from drug & device makers

$573in general payments, 2019–2025

Across 12 payments — averaging $47.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$240
  • Dexcom, Inc.$107
  • Neurocrine Biosciences, Inc.$102
  • Boston Scientific$21
  • Johnson & Johnson$19
  • GSK$18
  • plus $65 from 4 others

What the payments were for

  • Food & beverage$573100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$573 in reported general payments places this provider in the 60th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$50,269
Medicare patients
149
Services billed
853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin42$54,688
OzempicSemaglutide43$52,026
JanuviaSitagliptin Phosphate20$25,342
EliquisApixaban15$15,149
MyrbetriqMirabegron20$14,505
Tresiba Flextouch U-100Insulin Degludec11$7,779
Pregabalin11$4,025
SynthroidLevothyroxine Sodium24$2,838
Rosuvastatin Calcium186$1,782
Atorvastatin Calcium153$1,213
Losartan Potassium162$1,158
Albuterol Sulfate HfaAlbuterol Sulfate43$1,156
Levothyroxine Sodium117$968
Omeprazole97$929
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$882

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$18$52,02643 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Grand Blanc

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →